We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Investigator's Initiated Phase II Study for Pancreatic Cancer Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by Tzivia Berkman, Tiltan Pharma Ltd..
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: August 7, 2012
Last Update Posted: December 5, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Tzivia Berkman, Tiltan Pharma Ltd.
July 23, 2012
August 7, 2012
December 5, 2013
December 2013
October 2014   (Final data collection date for primary outcome measure)
Clinical Benefit Measurement [ Time Frame: Baseline up to 2 years ]
Clinical Benefit Measurement is a composite of measurements of pain (analgesic consumption and pain intensity), performance status and weight. Clinical benefit requires an improvement in at least one parameter, without worsening in any others, sustained for at least 4 weeks
Same as current
Complete list of historical versions of study NCT01659502 on ClinicalTrials.gov Archive Site
  • Safety and tolerability [ Time Frame: Baseline up to 2 years ]

    Safety and tolerability profiles will be judged by:

    • Local and systemic toxicities.
    • Number, type and degree of toxicities as measured by the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v4.0
  • Response Rate (RR) [ Time Frame: RR measured every 8 weeks after enrollment up to 2 years ]
  • Overall Survival [ Time Frame: OS measured at 16 and 52 weeks after treatment initiation or at death, whichever comes first up to 2 years ]
  • Progression Free Survival (PFS) [ Time Frame: PFS measured at 8 weeks after enrollment until the date of first documented progression or date of death, whichever comes first, up to 2 years ]
Same as current
Not Provided
Not Provided
Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
Not Provided
The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy.
Not Provided
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Pancreatic Cancer
Drug: TL-118
TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
Experimental: TL-118 alone or with pancreas cancer chemotherapy
Intervention: Drug: TL-118
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
October 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age at least 18 years at enrollment.
  2. Locally Advanced Pancreatic Cancer and/or Metastatic Pancreatic Cancer which failed to respond to one or two lines of chemotherapy
  3. The patient has histologically or cytologically confirmed pancreatic cancer.
  4. Patient has measurable disease by radiological imaging techniques as defined according to Response Evaluation Criteria in Solid Tumors (RECIST).
  5. ECOG performance status ≤ 2
  6. Adequate renal function.
  7. Adequate hepatic function
  8. Adequate bone marrow reserve -
  9. Resolution of prior therapy acute adverse events.
  10. Patient is capable of swallowing.
  11. Patient's Informed Consent.

Exclusion Criteria:

  1. Hypersensitivity to one or more of the TL-118 active components
  2. Known Glucose-6-phosphate-dehydrogenase deficiency (G6PD).
  3. Known CNS or Brain metastases
  4. Patient has received 3 or more different prior chemotherapies for the treatment of pancreatic cancer
  5. Any significant change in treatment within the 14 days before screening or an un-stable medical condition that may affect patient participation or evaluation in the study.
  6. Concurrent use of any other investigational product or within 28 days before study entry.
  7. Chronic treatment with: (a) immunosuppressive agent other than systemic corticosteroid, (b) patients who are under chronic treatment with NSAIDs with the exception of Aspirin at a daily dose ≤ 100mg.
  8. Use of supplements or complementary medicines/botanicals, except for conventional multivitamin supplements, calcium, selenium and soy supplements.
  9. Patients at increased risk of gastro intestinal bleeding such as patients with known active gastro intestinal ulcer, erosive gastritis or varices, as confirmed by gastroscopy performed within one year before screening.
  10. Serious or uncontrolled co-existent diseases that are likely to significantly increase the risks associated with TL-118 therapy (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection).
  11. Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C
  12. Serious or non-healing wound, ulcer or bone fracture.
  13. Circumstances likely to interfere with absorption of orally administrated drugs.
  14. History of noncompliance to medical regimens or coexisting conditions precluding full compliance with study protocol, or any other condition that in the discretion of the Investigator may preclude safe and complete study participation.
  15. Subjects unwilling or unable to comply with study protocol.
  16. Know pregnancy or breast-feeding women.
  17. Women of child bearing potential not exercising two methods of contraception.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Tzivia Berkman, Tiltan Pharma Ltd.
Tiltan Pharma Ltd.
Not Provided
Not Provided
Tiltan Pharma Ltd.
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP